Caribou Biosciences, Inc. (CRBU) Shareholder Alert: Robbins
SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) --
The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons or entities who purchased or acquired Caribou Biosciences, Inc. (NASDAQ: CRBU): (1) pursuant to the Offering Documents issued in connection with the Company's July 23, 2021 initial public offering ('IPO'); or (ii) between July 23, 2021 and December 9, 2022, for violations of the Securities Act of 1933 and Securities Exchange Act of 1934. Caribou is a clinical-stage biopharmaceutical company that engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the U.S. and internationally. The Company is developing CB-010, an allogeneic anti-CD19 CAR-T cell therapy1 that is in a Phase 1 clinical trial, referred to as “ANTLER”, to treat relapsed or refractory B cell non-Hodgkin lymphoma (“r/r B-NHL”).
What Now: Similarly situated shareholders may be eligible to participate in the class action against Caribou. Shareholders who want to act as lead plaintiff for the class must file their papers by April 11, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
What is this Case аbout: Caribou Biosciences, Inc. (CRBU) Made False and Misleading Statements in Connection with its IPO Regarding the Viability of its Drug Candidate
According to the complaint, the registration statement filed in connection with the IPO was materially false and misleading because it failed to disclose that CB-010’s treatment effect was not as durable as defendants had led investors to believe, and accordingly, CB-010’s clinical and commercial prospects were overstated.
On June 10, 2022, Caribou issued a press release reporting “[p]ositive” data from the ANTLER Phase 1 clinical trial. Among other results, Caribou reported that “[a]t 6 months following the single dose of CB-010, [only] 40% of patients remained in CR [complete response] (2 of 5 patients) as of the May 13, 2022 data cutoff date”, prompting investor concern over the durability of the CB-010 treatment. On this news, Caribou’s stock price fell $1.78 per share, or 20.41%, to close at $6.94 per share on June 10, 2022.
Then, on December 12, 2022, Caribou issued a press release “report[ing] new 12-month clinical data from cohort 1 in the ongoing ANTLER Phase 1 trial, which [purportedly] show[ed] long-term durability following a single infusion of CB-010 at the initial dose level 1 (40x106 CAR-T cells).” Among other results, Caribou reported that “3 of 6 patients maintained a durable CR at 6 months” and “2 of 6 patients maintain a long-term CR at the 12 month scan and remain on the trial”, thereby confirming investor fears that the CB-010 treatment lacked significant durability. On this news, Caribou’s stock price fell $0.81 per share, or 9.03%, to close at $8.16 per share on December 12, 2022.
Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Caribou Biosciences, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contact: Aaron Dumas Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 adumas@robbinsllp.com (800) 350-6003 www.robbinsllp.com | https://www.facebook.com/RobbinsLLP/ https://www.linkedin.com/company/robbins-llp/ |

TIN LIÊN QUAN
CRBU Class Action Lawsuit Announced: Johnson Fistel
SAN DIEGO, Feb. 11, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of...
Vertex Energy, Inc. (VTNR) Shareholder Notice: Robbins LLP
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons...
Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice:
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all...
Mesoblast Financial Results and Corporate Update Webcast
NEW YORK, Feb. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
Notice of Filing Securities Class Action Against Global
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. has filed a federal securities class action in the United States District Court...
THỦ THUẬT HAY
Trải nghiệm tính năng Picture-in-Picture với phiên bản Chrome dành cho PC
Để trải nghiệm tính năng này trên trình duyệt Google Chrome dành cho máy tính, bạn tải về và cài đặt trước phiên bản Chrome Canary kèm tiện ích mở rộng Picture-in-Picture do lập trình viên Kasik96 phát triển.
3 cách đơn giản nhất để chụp ảnh màn hình trên Galaxy Note 9
Chụp màn hình để lưu trữ thông tin là một trong những thao tác chúng ta hay dùng khi sử dụng. Với Galaxy Note 9 có khá nhiều cách để thực hiện chức năng này.
Học cách kiếm tiền bằng Google Rewards trên Android
Google Rewards là ứng dụng miễn phí trên Play Store. Sau khi tải và mở ứng dụng lần đầu tiên, Google sẽ yêu cầu bạn trả lời vài câu hỏi về bản thân. Chúng rất dễ trả lời. Mục đích của chúng nhằm giúp công cụ tìm kiếm
ĐÁNH GIÁ NHANH
Mở hộp và đánh giá nhanh HTC U11+: smartphone màn hình tràn viền đầu tiên của HTC
HTC U11+ là chiếc smartphone có màn hình tràn viền đầu tiên của HTC, nó đã đáp ứng được những kỳ vọng của người dùng khi là sự nâng cấp hoàn hảo của HTC U11.
Đánh giá nhanh khả năng chơi game của Huawei Y9 với Liên quân và PUBG
Chắc chắn Liên quân sẽ luôn luôn chơi mượt mà với các dòng máy tầm trung. Huawei Y9 có khả năng gánh được rất tốt tựa game này. Trong quá trình chơi, mình cũng không thấy có hiện tượng giật, lag hay sụt giảm khung